Treating inflammation using LLP2A-bisphosphonate conjugates and mesenchymal stem cells

Treating inflammation using LLP2A-bisphosphonate conjugates and mesenchymal stem cells

  • CN 105,636,596 A
  • Filed: 10/03/2014
  • Published: 06/01/2016
  • Est. Priority Date: 10/04/2013
  • Status: Active Application
First Claim
Patent Images

1. the method that a treatment has the object of idiopathic inflammatory disease or disorder, described idiopathic inflammatory disease or disorder are selected from:

  • arthritis, inflammatory arthritis, rheumatoid arthritis, synovitis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriasis arthropathica, spondylarthritis and osteoarthritis, described method includes;

    gives described object and comprises the LLP2A compositions intending the conjugate of peptide ligand and diphosphate/ester medicine, wherein, the compositions comprising described conjugate can improve the mescenchymal stem cell delivery to inflammatory sites.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×